Interactions Between Megakaryocytes and Tumour Cells at the Bone Marrow Vascular Stem Cell Niche Promote Tumour Growth and Metastasis
Psaila B. et al, (2009), BLOOD, 114, 194 - 194
Drosophila Larp associates with poly(A)-binding protein and is required for male fertility and syncytial embryo development.
Blagden SP. et al, (2009), Dev Biol, 334, 186 - 197
Megakaryocytes and the vascular niche in bone marrow metastasis
Psaila B. et al, (2009), CLINICAL & EXPERIMENTAL METASTASIS, 26, 892 - 892
Promising molecular targets in ovarian cancer.
Blagden S. and Gabra H., (2009), Curr Opin Oncol, 21, 412 - 419
Erratum: AAA phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancer (British Journal of Cancer (2008) 98: (1614-1618) DOI: 10.1038/sj.bjc.6604366))
Khan OA. et al, (2009), British Journal of Cancer, 101
Societal preference values for advanced melanoma health states in the United Kingdom and Australia.
Beusterien KM. et al, (2009), Br J Cancer, 101, 387 - 389
Cytolytic T-cell response to the PASD1 cancer testis antigen in patients with diffuse large B-cell lymphoma.
Ait-Tahar K. et al, (2009), Br J Haematol, 146, 396 - 407
A phase I dose escalation study of the pharmacokinetics and tolerability of ZK 304709, an oral multi-targeted growth inhibitor (MTGI), in patients with advanced solid tumours.
Scott EN. et al, (2009), Cancer Chemother Pharmacol, 64, 425 - 429
Chemotherapy-based treatment of metastatic melanoma
Atkins MB. et al, (2009), Cutaneous Melanoma, Fifth Edition
EXPRESSION AND EPIGENETIC ANALYSIS OF KEY B-LINEAGE TRANSCRIPTIONAL PROGRAMMES IN HODGKIN/uREED-STERNBERG CELLS
Collins GP. et al, (2009), HAEMATOLOGICA, 94, 36 - 36
EXPRESSION AND EPIGENETIC ANALYSIS OF KEY B-LINEAGE TRANSCRIPTIONAL PROGRAMMES IN HODGKIN/REED-STERNBERG CELLS
Collins GP. et al, (2009), HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 94, 36 - 36
Prognostic significance of immunohistochemical markers in endometrial cancer treated with chemotherapy
lord S. et al, (2009), J Clin Oncol 27, 2009
A phase I study of pazopanib in combination with FOLFOX 6 or capeOx in subjects with colorectal cancer.
Brady J. et al, (2009), J Clin Oncol, 27
A phase I study of pazopanib in combination with FOLFOX 6 or capeOx in subjects with colorectal cancer
Brady J. et al, (2009), JOURNAL OF CLINICAL ONCOLOGY, 27
Phase I first-in-human study of the polo-like kinase-1 selective inhibitor, GSK461364, in patients with advanced solid tumors.
Olmos D. et al, (2009), J Clin Oncol, 27
Phase II trial of nemorubicin hydrocloride (nemorubicin) in combination with cisplatin (cDDP) in patients (pts) with hepatocellular carcinoma (HCC): First step results
Izzo F. et al, (2009), JOURNAL OF CLINICAL ONCOLOGY, 27
Cells deficient in the base excision repair protein, DNA polymerase beta, are hypersensitive to oxaliplatin chemotherapy: A scientific rationale for chemo-radiation treatment
Nicolay N. et al, (2009), CANCER RESEARCH, 69
A phase I study of extended dosing with lomeguatrib with temozolomide in patients with advanced melanoma.
Kefford RF. et al, (2009), Br J Cancer, 100, 1245 - 1249
O(6)-methylguanine-DNA methyltransferase depletion and DNA damage in patients with melanoma treated with temozolomide alone or with lomeguatrib.
Watson AJ. et al, (2009), Br J Cancer, 100, 1250 - 1256